<DOC>
	<DOCNO>NCT01638546</DOCNO>
	<brief_summary>This randomized phase II trial study well temozolomide without veliparib work treat patient small cell lung cancer return respond treatment . Temozolomide work damage molecule inside cancer cell , deoxyribonucleic acid ( DNA ) , need cancer survival growth . Veliparib may stop growth tumor cell block protein need repair damage DNA may also help temozolomide kill cancer cell . It yet know whether temozolomide effective without veliparib treat patient relapse refractory small cell lung cancer .</brief_summary>
	<brief_title>Temozolomide With Without Veliparib Treating Patients With Relapsed Refractory Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To demonstrate improvement progression free survival ( PFS ) four month patient relapse sensitive refractory small cell lung cancer ( SCLC ) receive ABT-888 ( veliparib ) temozolomide compare placebo temozolomide . SECONDARY OBJECTIVES : I . Determine objective response rate ( ORR ) ( base Response Evaluation Criteria Solid Tumors [ RECIST ] 1.1 criterion ) arm study : ABT-888 temozolomide placebo temozolomide . II . Determine overall survival ( OS ) patient arm study . III . Determine ORR , PFS OS ABT-888 temozolomide placebo temozolomide , follow patient group : sensitive disease vs. refractory disease ; second-line treatment vs. third-line treatment ; brain metastasis vs. brain metastasis . IV . Determine safety tolerability ABT-888 temozolomide patient SCLC . TERTIARY OBJECTIVES : I . Evaluate available tumor sample methylated O6-methylguanine-DNA methyltransferase ( MGMT ) promoter EpiTyper assay , well MGMT expression immunohistochemistry determine correlate PFS , ORR , OS . II . Evaluate available tumor sample poly ( ADP ribose ) polymerase ( PARP ) -1 , breast cancer 1 ( BRCA-1 ) RAD51 recombinase ( RAD51 ) expression immunohistochemistry determine correlate PFS , ORR , OS . III . Evaluate available tumor sample messenger ribonucleic acid ( mRNA ) BRCA-1 expression determine correlate PFS , ORR , OS . IV . Evaluate available tumor sample phosphatase tensin homolog ( PTEN ) expression immunohistochemistry determine correlate PFS , ORR , OS . V. Identify enumerate circulate tumor cell ( CTCs ) use Cell Search System patient SCLC baseline time repeat image . VI . Correlate number CTCs PFS OS time point . VII . Correlate change CTCs radiographic response . VIII . Correlate number CTCs baseline patient characteristic ( disease burden , location metastasis , progression exist site new site disease ) . IX . Evaluate gamma H2A histone family , member X ( H2AX ) -positive CTCs use CellSearch . X. Assess percentage increase DNA fragment treatment correlate outcome treatment group . XI . Evaluate plasma marker apoptosis angiogenesis . XII . Assess change plasma marker apoptosis angiogenesis , include caspase-cleaved cytokeratin 18 fragment ( M30 ) , soluble cytokeratin 18 ( M65 ) , pro-gastrin-releasing peptide ( pro-GRP ) , soluble vascular endothelial growth factor ( sVEGF ) , sVEGF receptor 2 ( sVEGFR2 ) , soluble v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog ( sKIT ) , correlate marker outcome two treatment arm . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive veliparib orally ( PO ) twice daily ( BID ) day 1-7 temozolomide PO day 1-5 . ARM II : Patients receive placebo PO BID day 1-7 temozolomide Arm I . In arm , course repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 8-12 week .</detailed_description>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<criteria>Patients must histologically cytologically confirm small cell lung cancer ; confirmation do Memorial SloanKettering Cancer Center ( MSKCC ) locally participate site Patients ' disease relapse progressed one two prior chemotherapy regimen , one must etoposideplatinum doublet ; eligible patient define follow : `` Sensitive '' disease : patient one previous line chemotherapy maintain appropriate response &gt; 60 day `` Refractory '' disease : patient either ( ) response firstline chemotherapy progression = &lt; 60 day complete treatment , ( b ) `` sensitive '' `` refractory '' disease need thirdline therapy ( i.e . complete fail two previous line chemotherapy ) Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 1 ( Karnofsky &gt; = 70 % ) Patients asymptomatic brain metastasis require immediate whole brain radiation therapy stable dos steroid allow Patients must measurable disease , define least one lesion accurately measure least one dimension compute tomography ( CT ) scan per RECIST version 1.1 ; brain metastasis consider measurable disease meet criterion Absolute neutrophil count &gt; = 1,500/mcL Platelets &gt; = 100,000/mcL Hemoglobin &gt; = 8.5 g/dL ; use transfusion achieve criterion discretion investigator Total bilirubin = &lt; 1.5 mg/dL x institutional upper limit normal Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 3.0 x institutional upper limit normal Creatinine = &lt; 1.5 x institutional upper limit normal OR creatinine clearance &gt; = 50 mL/min/1.73 m^2 patient creatinine level &gt; = 1.5 x upper limit institutional normal Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately For woman childbearing potential , negative pregnancy test within 14 day prior start temozolomide ABT888 Ability understand willingness sign write informed consent document Able swallow pill Patients exclude base diagnosis acquire immune deficiency syndrome ( AIDS ) ; give increase risk infection , patient cluster differentiation ( CD ) 4 count 200 cells/mm^3 ; patient AIDS human immunodeficiency virus ( HIV ) receive agent potential pharmacokinetic interaction ABT888 may eligible Patients chemotherapy radiotherapy within 3 week prior enter study Patients recover adverse event due agent administer 3 week earlier ; toxicity resolve baseline within one grade level baseline ( exceed grade 2 ) Patients administer ABT888 , PARPinhibitor , temozolomide Patients may receive investigational agent Patients leptomeningeal involvement Patients active seizure history seizure History allergic reaction attribute compound similar chemical biologic composition ABT888 temozolomide Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue mother treated ABT888 ; potential risk also apply temozolomide Patients either AIDS HIV combination antiretroviral therapy ineligible Patients synchronous active malignancy require treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>